Chromadex Corp (NASDAQ:CDXC) does about 1.06M shares in volume on a normal day but saw 1433177 shares change hands in the recent trading day. The company now has a market cap of 525.99M USD. Its current market price is $7.27, marking an increase of 6.60% compared to the previous close of $6.82. The 52 week high reached by this stock is $7.58 whilst the lowest price level in 52 weeks is $1.32.
Chromadex Corp (CDXC) has a 20-day trading average at $5.44 and the current price is -4.09% off the 52-week high compared with 450.76% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.28 and its 200-day simple moving average is $3.26. If we look at the stock’s price movements over the week, volatility stands at 7.53%, which increases to 9.44% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 73.22 to suggest the stock is overbought.
The consensus objective for the share price is $8.70, suggesting that the stock has a potential upside of 16.44% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
B. Riley Securities also downgraded the stock to “Neutral” from Buy on August 11, 2022 at a price target of $6-$2.40. ROTH Capital initiated its price target at $7.
The current price level is 33.71%, 69.79%, and 123.14% away from its SMA20, SMA50, and SMA200 respectively, with the CDXC price moving below the 50-day SMA on current market day. Chromadex Corp (CDXC) stock is up 3.71% over the week and 107.71% over the past month. Its price is 408.39% year-to-date and 397.95% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/30/2024, with the company’s earnings per share (EPS) of 0 above consensus estimates by 0.02. The company’s next earnings report forecasts estimating quarterly EPS at 0.02 and 0.04 for whole year. Expected sales for next quarter are $27.74M, which analysts say will come at $96.94M for the current fiscal year and next year at $118.31M. In addition, estimates put the company’s current quarterly revenue at an average of $26.52M.
To reach the target analysts have set, the stock logically needs to grow 16.44 percent from here.
Outstanding shares total 74.98M with insiders holding 35.39% of the shares and institutional holders owning 23.87% of the company’s common stock. The company has a return on investment of 4.10% and return on equity of 4.82%. The price to earnings ratio (P/E ratio) amounts to 384.66 while the forward price to earnings ratio is 54.87. The beta has a value of 1.95. Price to book ratio is 16.08 and price to sales ratio is 5.74.
